Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03406702 · ClinicalTrials.gov registry record · Phase 2
CX-8998 for Absence Seizures
A Phase 2 study of Epilepsy, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
- 7
- Study locations
NCT03406702: Completed Phase 2 study of Epilepsy, sponsored by Jazz Pharmaceuticals.
NCT03406702 is a Phase 2 study of Epilepsy that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 7 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03406702, a Phase 2 study of Epilepsy, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a Phase 2a, open-label study consisting of a screening period of up to 4 weeks and a 4-dose-titration treatment period to a dose of up to 10 mg twice daily (BID) of CX-8998, followed by a 1-week safety follow-up period after the last dose of study medication.
Primary Outcome
Fridericia's Correction Formula (QTCF) is a formula which takes into account the physiologic shortening of the QT interval which occurs as the heart rate increases, permitting comparison of the QT interval across a range of rates.
Conditions Studied
Interventions
- DRUG CX-8998
Study Locations (7)
Arkansas
- Arkansas Epilepsy Program - Little Rock
Florida
- University of Florida - Tampa
Kentucky
- Bluegrass Epilepsy Research, LLC - Lexington
Massachusetts
- Tufts Medical Center - Boston
New York
- NYU Comprehensive Epilepsy Center - New York
Ohio
- Cincinnati Children's Hospital - Cincinnati
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-02-25 |
| Est. Completion | 2019-03-29 |
| Phase | Phase 2 |
What the finished NCT03406702 record still lists
NCT03406702 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which CX-8998 is the first listed.
NCT03406702 lists 7 locations in 7 states (Arkansas, Florida, Kentucky).
Frequently Asked Questions
What is clinical trial NCT03406702 about?
NCT03406702 is a clinical study titled "CX-8998 for Absence Seizures". This is a Phase 2a, open-label study consisting of a screening period of up to 4 weeks and a 4-dose-titration treatment period to a dose of up to 10 mg twice daily (BID) of CX-8998, followed by a 1-week safety follow-up period after the last dose of study medication.
What is the current status of trial NCT03406702?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2018-02-25. Estimated completion is 2019-03-29.
What conditions does trial NCT03406702 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT03406702?
The interventions under investigation include: CX-8998 (DRUG).
Who is sponsoring clinical trial NCT03406702?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03406702 being conducted?
This trial has 7 study locations across Arkansas, Florida, Kentucky, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03406702's enrollment target sits among peer trials
7 154th of 160 higher than 7 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of an External Responsive Neurostimulator System on Epileptiform Activity
COMPLETED · Phase 2
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
COMPLETED · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI